Table 4: Changes in CK-MB, cTnI, h-FABP, NO, and vWF levels before and after PCI in the control and trimetazidine groups, expressed as  ± s.

ΔCK-MB (U/L)ΔcTnI (ng/mL)Δh-FABP (ng/mL)ΔNO (μmol/L)ΔvWF (ng/ml)

Control group4.77 ± 13.730.42 ± 0.780.06 ± 0.3724.19 ± 5.850.43 ± 0.72
Trimetazidine group0.23 ± 2.600.06 ± 0.370.04 ± 1.310.07 ± 7.900.19 ± 0.13
value0.0160.0350.6400.0100.002

ΔCK-MB: change in creatine kinase-muscle/brain, ΔcTnI: change in cardiac troponin I, Δh-FABP: change in heart-type fatty acid-binding protein, ΔNO: change in nitric oxide, and ΔvWF: change in von Willebrand factor. .